Posted: February 6, 2023 at 12:06 am
Where Does Summit Therapeutics Inc (SMMT) Stock Fall in the Biotechnology Field After It Is Up 8.63% This Week? InvestorsObserver
Go here to see the original:
Where Does Summit Therapeutics Inc (SMMT) Stock Fall in the Biotechnology Field After It Is Up 8.63% This Week? - InvestorsObserver
Posted: February 6, 2023 at 12:06 am
Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Down -2.89% This Week? InvestorsObserver
See the original post here:
Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Down -2.89% This Week? - InvestorsObserver
Posted: January 29, 2023 at 1:02 am
January 27, 2023
Excerpt from:
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
Posted: January 29, 2023 at 1:02 am
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
See the rest here:
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic...
Posted: January 29, 2023 at 1:02 am
REGULATED INFORMATION
Continued here:
BioSenic appoints Yves Sagot as Independent Director
Posted: January 29, 2023 at 1:02 am
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Read the original here:
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Posted: January 29, 2023 at 1:02 am
ORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Read more here:
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Posted: January 29, 2023 at 1:02 am
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company’s Board of Directors, effective February 26, 2023. Dr. Tran will be transitioning into public service commencing February 27, 2023, that will preclude her participation on the Arbutus and other pharmaceutical and biotechnology Boards.
Read the original:
Arbutus Announces Resignation of Board Member
Posted: January 29, 2023 at 1:02 am
Please read the full announcement in PDF
Go here to see the original:
Trading by management and close relations of management
Posted: January 29, 2023 at 1:02 am
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.
Link:
Amarin to Present at SVB Securities Global Biopharma Conference
